Oza, Amit

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 2,870

Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial

Zimmermann, C., Swami, N., Krzyzanowska, M., Hannon, B., Leighl, N., Oza, A., Moore, M., Rydall, A., Rodin, G., Tannock, I., et al. (2014) · The Lancet

Palliative Care and End-of-Life IssuesPalliative and Oncologic Care

Cited by 1,781

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 1,196

Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial

DiSilvestro, P., Banerjee, S., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., et al. (2023) · Journal of Clinical Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 511

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53 -mutant Ovarian Cancer

Oza, A. M., Estevez-Diz, M., Grischke, E.-M., Hall, M., Marmé, F., Provencher, D., Uyar, D., Weberpals, J. I., Wenham, R. M., Laing, N., et al. (2020) · Clinical Cancer Research

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 129

Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care

Miller, F. A., Hayeems, R. Z., Bytautas, J. P., Bedard, P. L., Ernst, S., Hirte, H., Hotte, S., Oza, A., Razak, A., Welch, S., et al. (2014) · European Journal of Human Genetics

BRCA gene mutations in cancerCancer Genomics and Diagnostics

Cited by 116

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2

Monk, B. J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D.-S., Oaknin, A., Ray-Coquard, I., Provencher, D. M., Karlan, B. Y., et al. (2016) · Gynecologic Oncology

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 98

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

Marth, C., Vergote, I., Scambia, G., Oberaigner, W., Clamp, A., Berger, R., Kurzeder, C., Colombo, N., Vuylsteke, P., Lorusso, D., et al. (2017) · European Journal of Cancer

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 79

Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study

Sjoquist, K. M., Friedlander, M. L., O'Connell, R. L., Voysey, M., King, M. T., Stockler, M. R., Oza, A. M., Gillies, K., Martyn, J. K., & Butow, P. N. (2013) · The Oncologist

Optimism, Hope, and Well-beingCancer survivorship and care

Cited by 43

Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate

Dranitsaris, G., Leung, P., Mather, J., & Oza, A. (2000) · Anti-Cancer Drugs

Health Systems, Economic Evaluations, Quality of LifeBreast Cancer Treatment Studies

Cited by 38

Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer

Marastoni, S., Madariaga, A., Pesic, A., Nair, S. N., Li, Z. J., Shalev, Z., Ketela, T., Colombo, I., Mandilaras, V., Cabanero, M., et al. (2022) · Cancer Research Communications

Ovarian cancer diagnosis and treatmentAutophagy in Disease and Therapy

Cited by 19